|
Bristol, TN March 8, 2010
Graceway Announces Journal of the American Academy of Dermatology Publishes Articles on New Short-Course Imiquimod Formulation in Actinic Keratosis
Data Suggest Short-Course Imiquimod 3.75% Produced Statistically Significant Outcomes ...
>>Read more
Bristol, TN February 12, 2010
Graceway Extends Partnership with NASCAR Camping World Truck Series Driver Aric Almirola; Adds Sprint Cup Series
Almirola Continues to Raise Awareness of Skin Health and Sun Safety ...
>>Read more
Bristol, TN January 5, 2010
Health Canada Approves Graceway Product for Precancerous Skin Condition
Patient-applied cream for actinic keratoses targets visible and sub-clinical lesions in short therapy treatment ...
>>Read more
Bristol, TN November 6, 2009
Graceway Pharmaceuticals Acquires Worldwide Rights to GS 9191 from Gilead Sciences
Graceway Pharmaceuticals, LLC, a portfolio company
of GTCR Golder Rauner, LLC, today announced ...
>>Read more
Bristol, TN July 31, 2009
Data Demonstrate New Imiquimod Formulation
as Short Course Treatment for Actinic Keratosis
FDA Accepts NDA for New Imiquimod Product ...
>>Read more
New York, NY July 1, 2009
Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) today announced ...
>>Read more
Bristol, TN May 29, 2008
Study in Journal of Pediatrics
ATOPICLAIR® is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children ...
>>Read more
Bristol, TN April 21, 2008
Study in New England Journal of Medicine
ALDARA® (imiquimod) Cream, 5% demonstrated a reduction in lesion size in patients with vulvar intraepithelial neoplasia (VIN) ...
>>Read more
Bristol, TN April 16, 2008
Study in British Journal of Dermatology
Patients Treated with ALDARA Experienced Higher Levels of Histological and Sustained Clearance for Actinic Keratosis than Patients in two Other Common AK Treatments ...
>>Read more
|
